Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Durvalumab Demonstrates Real-World PFS Benefit In Unresectable Stage III NSCLC
2 Adagrasib Demonstrates Promising Activity in KRAS G12C+ Advanced NSCLC
3 Rigosertib Plus Nivolumab Shows Encouraging Early Results in KRAS-Mutant NSCLC
4 In Unresectable Stage III NSCLC, Real-World PFS Benefit Reported With PACIFIC Regimen
5 Blood-Based TMB Is Not Predictive of Benefit With Atezolizumab in NSCLC
6 Study Will Collect Patient Preferences for NSCLC Treatments
7 Phase III data shows Roche's Tecentriq addressing unmet need in NSCLC
8 Sitravatinib Plus Nivolumab Induces Durable Responses in Advanced NSCLC After ICIs, Chemotherapy
9 Robust Antitumor Activity Observed in Advanced RET Fusion+ NSCLC With Selpercatinib
10 Datopotamab Deruxtecan Shows Safe Antitumor Activity in Advanced NSCLC With Genomic Alterations
11 Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC
12 Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status
13 Immune-Related AEs Predict Positive Outcomes in NSCLC
14 ESMO Data Shed Light on Activity of Janssen's Rybrevant-Leclaza Combo in EGFR-Mutated NSCLC
15 Trastuzumab Deruxtecan Yields Robust Antitumor Responses in HER2+ NSCLC
16 Atezolizumab Combo Demonstrates Favorable Efficacy and Safety Data for NSCLC with Untreated Brain Metastases
17 Adjuvant Atezolizumab Improves DFS While Delaying Relapse in NSCLC Subgroups
18 Novel Immunotherapy Options Prompt Paradigm Shift in NSCLC Treatment
19 FDA approves Exkivity for NSCLC subset
20 Novel drug combinations improve progression-free survival for patients with advanced NSCLC
21 OncoHost Further Assessing Protein Signature for Predicting NSCLC Patients' Immunotherapy Response
22 New Hope for NSCLC Patients With EGFR Exon 20 Insertion... : Oncology Times
23 Pelcitoclax Plus Osimertinib Shows Promise in Patients With EGFR TKI–Resistant NSCLC
24 Immunotherapy for NSCLC: Clinical Pearls
25 NSCLC: Overcoming Challenges
26 Lasting Response With Sitravatinib Plus Nivolumab Observed After Previous Checkpoint Inhibitors and Chemotherapy For Advanced NSCLC
27 Osimertinib/Bevacizumab Combo Does Not Improve PFS in EGFR-Mutant NSCLC
28 Dr. Garon on the Efficacy of Datopotamab Deruxtecan in NSCLC
29 Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC?
30 Nivolumab and Tumor-Infiltrating Lymphocyte Regimen Elicits Activity in Metastatic NSCLC
31 EXKIVITY® (mobocertinib) Approved for Previously-Treated Adult Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
32 Lyudmila Bazhenova, MD, Discusses the Reasoning Behind Testing for EGFR Exon 20 Insertions in NSCLC at 2021 WCLC
33 Blood-Based Biomarkers in NSCLC
34 Tolerable Phase 2 Dose of Mobocertinib in Japanese Patients With NSCLC Consistent With Global Maximum-Tolerated Dose
35 Clinical Responses to Sotorasib Could Vary by Co-Mutational Status in NSCLC
36 'Urgent' Need to Understand Immunotherapy De-escalation in NSCLC
37 NSCLC and hyponatremia: Connection, treatment, and more
38 Extended Interval Dosing With Zoledronic Acid in Metastatic SCLC and NSCLC Appears to Be a Safe and Reasonable Option
39 Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers
40 PFS Benefit Observed With Tislelizumab Plus Chemotherapy for Advanced Squamous NSCLC
41 First-line durvalumab-tremelimumab regimen improves outcomes in NSCLC subset
42 Hypofractionated Image-Guided Versus Conventionally Fractionated Radiotherapy Shows No Treatment Advantage in NSCLC With Poor Performance Status
43 Survey Gathers Insights into NSCLC Management to Inform Improvements to Care
44 Intracranial Activity Seen With Sotorasib for KRAS G12C–Mutated NSCLC Brain Metastases
45 Sugemalimab Treatment for Stage 4 NSCLC Prolongs Progression-Free-Survival
46 Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC
47 Durable Response with Immunotherapy Combos in NSCLC with Brain Metastases
48 Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage NSCLC
49 Investigators Initiate Treatment With ERAS-007 in Patients With EGFR-Positive NSCLC
50 Roundtable Discussion: Antonoff Discusses Treatment Goals in NSCLC
51 Older adults with late-stage NSCLC benefit from immunotherapy
52 Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC
53 WCLC: AstraZeneca's detailed Imfinzi, tremelimumab data in metastatic NSCLC are far from a clear-cut win
54 Mobocertinib Elicits Efficacy in Advanced EGFR Exon 20 Insertion+ NSCLC Regardless of Prior Immunotherapy
55 Patients With ALK+ NSCLC Not Suitable for Crizotinib Benefit from Sequential ALK-Inhibitor Therapy
56 Beyondspring NSCLC phase III hits primary endpoint but stock sags anyway
57 Encouraging Overall Response Rate Reported With Domvanalimab-Combinations in Non-Small Cell Lung Cancer
58 MIL60 Bevacizumab Biosimilar Candidate Demonstrates Equivalence in NSCLC
59 Dual Immunotherapy Boosts Survival in Metastatic NSCLC
60 Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States
61 Imfinzi™ and tremelimumab combo improves NSCLC outcomes
62 No Survival Bump With PARP Inhibitor in Squamous NSCLC
63 NSCLC gene therapy: Success rate, other options, and more
64 Treatment and survival in advanced non-small cell lung cancer, urothelial, ovarian, gastric and kidney cancer: A nationwide comprehensive evaluation
65 More Precise NSCLC Treatment Selection Boosted by Using EGFR Mutation Structure and Function
66 Ensartinib Tops Crizotinib in ALK-Positive NSCLC
67 Hypofractionated Radiotherapy Fails to Extend Survival in NSCLC Patients Ineligible for Concurrent Chemoradiotherapy
68 Oncologists Bemoan 'Lousy' PD-L1 Biomarker in Light of New Adjuvant Tecentriq NSCLC Study Data
69 NSCLC: Final Thoughts
70 Dr. Patil on ADAURA Data with Osimertinib in NSCLC
71 Clinical Activity Shown With Mobocertinib in Advanced EGFR Exon 20 Insertion+ NSCLC, Regardless of Prior I/O
72 Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC
73 Adjuvant Atezolizumab Improves DFS in Early-Stage NSCLC Across Most Disease Stages and Prior Therapies
74 Several Companies Tout Lung Cancer Breakthroughs at ESMO 2021
75 Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
76 Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC
77 Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases
78 ALK Inhibitor Success Prompts Search for a Role Beyond NSCLC
79 Mobocertinib Elicits Antitumor Activity in EGFR Exon 20 Insertion+ NSCLC After Disease Control With EGFR TKIs
80 Spectrum Pharmaceuticals Announces Late-Breaking Oral Presentation of Data for Poziotinib in First-Line NSCLC Patients with HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2021
81 EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
82 Targeted Drug ROS1 Inhibitors For NSCLC Market Size, Trends, and Key Companies – Roche, Beacon Pharma Limited, Pfizer, Drug International Limited, Incepta Pharmaceuticals, Genentech Inc., Bayer – Stillwater Current
83 Significance of PD-L1/PD-1 Testing in NSCLC
84 Clinical Pearls: EGFR Exon 20 Insertion+ NSCLC Treatment
85 Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
86 Small cell lung cancer tumor markers: Types, ranges, and more
87 Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
88 Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress
89 Brigatinib Maintains Superior PFS Benefit Over Crizotinib With High Intracranial Efficacy in ALK+ NSCLC
90 Sequential Therapy With Crizotinib Followed by Alectinib May Improve Survival in ALK+ NSCLC
91 Pipeline Watch: Phase III Readouts In NSCLC, Ovarian Cancer And More
92 EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
93 BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Me
94 IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
95 Angle PLC Announces Study Shows Use of Parsortix to Assess PD-L1
96 ALK Inhibitors Help to Define Precision Medicine
97 Non-small cell lung cancer: Stages and treatments
98 А phase III study proven the efficacy of the bevacizumab biosimilar BCD-021 in patients with late stages of non-squamous non-small cell lung cancer (NSCLC)
99 Spectrum Pharma (SPPI) Presents Cohort 4 Data of ZENITH20 Clinical Trial
100 Health Canada approves LUMAKRAS™ (sotorasib), the first and only targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer